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Summary
Nitric oxide’s expansive physiological and regulatory roles have driven the development of
therapies for human disease that would benefit from exogenous NO administration. Already a
number of therapies utilizing gaseous NO or NO donors capable of storing and delivering NO
have been proposed and designed to exploit NO’s influence on the cardiovascular system, cancer
biology, the immune response, and wound healing. As described in Nitric Oxide Release Part I:
Macromolecular Scaffolds and Part II: Therapeutic Applications, the preparation of new NO-
release strategies/formulations and the study of their therapeutic utility are increasing rapidly.
However, comparison of such studies remains difficult due to the diversity of scaffolds, NO
measurement strategies, and reporting methods employed across disciplines. This tutorial review
highlights useful analytical techniques for the detection and measurement of NO. We also stress
the importance of reporting NO delivery characteristics to allow appropriate comparison of NO
between studies as a function of material and intended application.
1. Introduction
Nitric oxide is endogenously generated by a heme-containing enzyme called nitric oxide
synthase (NOS) via the 5-electron oxidation of the amino acid L-arginine to L-citrulline
generating one equivalent of NO.1, 2 Due to the importance of NO in a number of signaling
pathways, interruption in the homeostasis of the NOS enzymes directly or indirectly may
lead to and/or is characteristic of a particular disease state.3 As such, therapeutics that either
regulate NOS activity or produce NO exogenously have become an important research area.
Indeed, the number of scaffolds that chemically store and deliver NO include NO-releasing
proteins,4 nanoparticles,5, 6 and polymers7, 8 (see Nitric Oxide Release Part I:
Macromolecular Scaffolds). These exogenous sources of NO have been investigated as
potential medicinal agents for cardiovascular,2, 9 cancer,10 antibacterial,11, 12 and wound
healing11, 13 therapies as discussed in Nitric Oxide Release Part II: Therapeutic
Applications. However, the knowledge that NO’s effects are concentration-dependent
demands accurate quantification and reporting of the NO levels released from such scaffolds
to determine which formulations are most promising and suitable for specific therapeutic
applications. Although a number of analytical methods are available to quantify NO, this
review provides a comparison of the three most common techniques: Griess reaction,14, 15
chemiluminescence,14, 16 and electrochemistry.14, 17, 18 Equally important, we stress the
need for reporting exogenous NO delivery with respect to the NO release vehicle (i.e., gas,
NO donor, formulation) and amount (i.e., volume, mass, surface area). Careful and
consistent reporting criteria are vital to both understanding and disseminating the
concentration dependence of NO’s beneficial and detrimental influence on biology.3, 19–31
Many initial studies of NO’s importance to physiology have focused on exposing biological
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As shown in Table 1, these works have contributed to the realization that NO’s biological
activity is concentration dependent.3 At low concentrations (< 1–30 nM), NO functions
primarily through a cGMP-dependent pathway.19, 20 The activation of soluble guanylyl
cyclase (sGC) triggers a reaction cascade that ultimately results in the vasodilatory and
angiogenic effects common to NO.20 As NO concentrations rise, NO induces
phosphorylation of protein kinases that may subsequently initiate apoptosis protection.21–24
For example, phosphorylation of the pro-apoptotic protein Bad promotes its sequestration in
the cytoplasm thereby preventing reaction with target genes in the nucleus and reducing the
incidence of Bad-triggered apoptotic events.25 As NO concentrations approach 100 nM,
tissue injury protection is also observed.26, 27 HIF-1α, a protein that mediates hypoxic
effects on tissues, becomes stabilized and in turn regulates the effects of low oxygen
concentration on vital cellular mechanisms.27 Whereas NO concentrations <100 nM result in
protection against apoptosis, the effects of NO at concentrations >400 nM induce pro-
apoptotic responses that are particularly important for antibacterial and anticancer
applications.28 For example, phosphorylation of p53, a cell cycle regulator, occurs at
elevated NO concentrations and results in protein activation and subsequent cell cycle
arrest.28 Concentrations of NO approaching and exceeding 1 µM similarly result in
apoptotic effects via protein nitrosation.29–31 In summary, low concentrations of NO have
been linked to protective and anti-apoptotic action while larger NO concentrations often
result in apoptosis and full cell cycle arrest.
2. Measuring Nitric Oxide
2.1 Challenges of Measuring NO
Understanding the effects of specific NO concentrations administered to physiological loci
is crucial. However, NO’s rapid diffusion, high reactivity, and short half-life make accurate
and precise measurements challenging.14 When NO is administered over a period of time,
insight into both instantaneous NO concentrations and total amounts of NO delivered is
required to properly evaluate the efficacy of NO as a therapeutic. Furthermore, the system in
which NO measurements are performed must closely mimic the environment of the
proposed application. For example, the amount of available NO released from a material in
blood will be significantly lower than when the same material is placed in phosphate
buffered saline. Additionally, only those NO-release triggers relevant to the intended
application should be utilized as obviously the NO release mechanism will dictate NO flux
and duration. For example, NO released from a nitrosothiol-based NO donor proposed for a
systemic application should only be triggered by physiologically relevant conditions (e.g.,
37 °C or glutathione, not light). Next, we introduce the three most popular analytical
methods for measuring NO in biologically relevant media. Highlights of the basic
methodology, limits of detection, detection ranges, and interferences associated with these
measurement techniques are discussed to provide insight on the most ideal method for a
particular NO release scaffold and/or application.
2.2 Griess Assay
The Griess assay is the most popular method for the analysis of NO based on price (low
cost), simple execution, and straightforward data analysis.14 First developed in 1879, the
Griess assay measures NO indirectly as nitrite (NO2−), a product of NO’s autooxidation.32
As shown in Scheme 2, NO2− reacts with sulfanilamide to form a diazonium salt
intermediate that subsequently reacts with N-(1-napthyl)ethylenediamine to form an azo
dye. The formation of the azo dye is then monitored spectroscopically at 540 nm.
As shown in Figure 1, NO that is released from the sample is converted to NO2− that
subsequently reacts with the Griess reagents (sulfanilamide and N-(1-
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napthyl)ethylenediamine). Following this reaction, the absorbance of the solution is
measured and compared to the absorbance of similarly treated NO2− standards via a
calibration curve. Of note, care should be taken to remove the scaffold or any other species
from the analyte solution that may skew absorbance measurements. Assuming that NO2−
was not formed as a byproduct during the synthesis/evaluation of a given NO-release
scaffold, the NO2− concentration measured is proportional to the concentration of NO
released. As such, solutions containing nitrite and/or materials that liberate nitrite and NO
will result in erroneous data unless care is taken to resolve nitrite from NO. The limit of
detection for commercially available Griess reagent kits is roughly 2.5 µM in ultrapure
deionized distilled water.33 Unfortunately, the sensitivity of the Griess assay is highly
dependent on solution composition (i.e., buffer and matrix), and thus often results in non-
uniform dynamic ranges and varying limits of detection for different systems. Furthermore,
the reaction of NO and oxygen may form other decomposition products such as nitrate
(NO3−), resulting in superficially low NO values.34 Real-time analysis of NO generation
using the Griess assay is not possible due to both the necessary chemical reactions and the
indirect nature of detection. Despite such drawbacks, the commercial availability of reagent
kits and the ability to employ high throughput 96-well microtiter plates make it a useful
method for studying NO release. Nevertheless, care must be taken in reporting NO release
using the Griess assay, particularly for quantitative work (e.g., correlating NO concentration
and/or reaction kinetics to biological activity) since this assay will overestimate NO in the
presence of nitrite and/or nitrite release.
2.3 Chemiluminescence
Although more costly due to the required instrumentation and maintenance, NO analysis by
chemiluminescence provides significantly more detailed information about NO release. In
contrast to the Griess assay, NO is measured directly using chemiluminescence. Thus,
precautions must be taken to minimize side reactions of NO before analysis as these will
lead to artificially low concentrations. In particular, the system (i.e, media, flask) must be
free of oxygen to reduce depletion of NO (via nitrogen dioxide formation) prior to analysis.
After establishing an anaerobic environment, the NO-releasing material may then be
introduced and monitored.
The NO that is produced or present is then carried by a continuously flowing stream of inert
gas (i.e., nitrogen or argon) to a reaction cell within the chemiluminescence instrument
(Figure 2). In the reaction cell, NO reacts with ozone that is generated in situ to form
nitrogen dioxide in its excited state (NO2*). The subsequent decay of NO2* to its ground
state results in the emission of a photon (between 600–875 nm) that is measured using a
photomultiplier tube (PMT).16 In this respect, the analytical signal is proportional to the
instantaneous concentration of NO.14, 16 Optical filters may be placed in front of the PMT to
prevent interferences from other species that may react with ozone (e.g., ethylenes,
carbonyls, sulfur compounds).16 The gas phase analysis requires the use of a carrier gas,
which prevents the transfer of water soluble interferents including nitrite and nitrate that
may be present in the sample flask. A standard calibration curve is constructed using a NO
filter as a zero point and commercially available premixed nitric oxide gases of known
concentrations. Of note, the method by which the calibration gases are introduced to the
instrument should mimic the experimental setup as closely as possible. Commercially
available chemiluminescence instruments offer numerous advantages for quantifying NO,
including minimal response to interfering species, a wide dynamic linear range (typically 0.5
ppb to 500 ppm NO), and near real-time monitoring that is essential for assessing NO’s
transient behavior.35 Of note, the NO levels measured are highly dependent on the system
(vessel) configuration, flow rate (pressure) of the carrier gas, and deadspace between the
sample and the reaction cell. Changes in these parameters during a given experiment will
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greatly influence the ensuing data particularly kinetics of NO release. Lastly, the system
must be well sealed (i.e, free of leaks) to ensure all NO is carried to the analyzer.
2.4 Electrochemistry
In contrast to chemiluminescence analysis, electrochemistry and more specifically the use of
electrochemical sensors and related instrumentation are more economical, easily
miniaturized, and capable of in situ NO analysis.18 As shown in Figure 3, the
electrochemical detection of NO released from a sample may be carried out via either a two
electron reduction of NO to N2O22− (at −0.5 to −1.4 V vs. Ag/AgCl)36 or the more
commonly used three-step three-electron oxidation of NO to NO3− (at 0.6 to 0.9 V vs. Ag/
AgCl).17 Current is measured and compared to a calibration curve to determine the
concentration of NO.
While electroreduction is promising due to a decrease in the effect of interfering species, its
utility is limited by poor sensitivity, oxygen interference, and diminished response at
physiological pH.18 Alternatively, electrooxidation is characterized by enhanced sensitivity
and utility at physiological pH and represents the preferred method of electrochemical NO
detection despite interference from numerous biological species (i.e., carbon monoxide,
acetaminophen, nitrite, dopamine).18 Selectivity over interfering species is often required
when measuring small concentrations of NO and may be achieved by coating the electrode
with a permselective polymer membrane. Nafion,37 polystyrene36 and
(heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane xerogel membranes38 have all
been used as sensor membranes to enhance NO selectivity by decreasing/eliminating
diffusion of ionic interferents through the membrane coating. Due to the wide variety of
permselective polymers employed as NO sensor membranes, sensitivity for NO and
selectivity over interfering species vary widely based on sensor design. To date, limits of
detection for NO as low as 83 pM have been reported with dynamic linear ranges of 0.2 nM
– 4.0 µM.38 The ability of these sensor platforms to be miniaturized and used for real-time
measurements in biological milieu represents a significant advantage for using
electrochemistry over alternative methods of NO detection. Furthermore, the small size of
many NO sensor platforms allows for detection at/near the NO source, minimizing analyte
loss due NO’s inherent reactivity.18 Although long-term sensor performance is often
compromised in complex environments (i.e., in situ or in vivo), sensors are generally
affordable and thus electrochemical detection remains a popular method for NO analysis.
3. Reporting Nitric Oxide Release
The formulation and investigation of potential NO-release scaffolds as therapeutics have
increased due to the physiological and medicinal effects attributed to NO. The range of
biomedical applications for NO may necessitate multiple formulations including gaseous
NO, low molecular weight molecules, and macromolecular particles, gels and coatings. For
example, polymeric device coatings capable of releasing NO in a controlled manner have
been shown to decrease bacterial infection and improve tissue integration and/or blood
compatibility for subcutaneous glucose sensors,7, 39 orthopedic devices,40, 41 and vascular
stents.42 Macromolecular NO release scaffolds are also being developed as stand-alone
therapeutics against pathogens43, 44 and cancer,10 with much of their efficacy related to their
ability to deliver large NO payloads directly to cells. Due to the assorted methods for
measuring NO and the related diverse data, direct comparison across NO release scaffold
types is both challenging and important. Unfortunately, reports of NO release characteristics
often do not contain sufficient information for understanding and comparing therapeutic
efficacy. The rate of release, NO flux, release duration, and release half-life all represent
essential parameters for describing a NO source. Furthermore, NO release characteristics
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must be normalized to the amount/volume of the source (e.g., scaffold) for accurate
representation of therapeutic efficacy.
3.1 Surface-generated NO Release
The release of NO from a surface is attractive for antibacterial and antithrombic
applications. For example, NO-releasing coatings on medical implants may prevent
infection and device-induced thrombosis/restenosis (as discussed in Nitric Oxide Release
Part II. Therapeutic Applications). Depending on the characteristics of the implant, surface-
generated NO may be achieved by various means including self-assembled monolayers
(SAMs) of NO donors on metal and silica surfaces45, 46 or the casting of thin polymer films
on substrates.8, 47, 48 The thickness of a coating will impact NO release duration and flux; it
is thus essential to report the total amount of material deposited on the substrate or device
used for analysis. The total NO release ([NO]T) must then be normalized per unit mass of
the material deposited (mol NO mg−1) and per unit area (mol NO cm−2) of the coated
material.
Other parameters that should be used to characterize NO release include the duration (td)
and half-life of release (t1/2) to indicate the period over which the scaffold actively releases
NO (Figure 4A). In addition to [NO]T and td, the amounts of NO released at specific times
within the lifetime of the NO-releasing polymer are arguably the most important NO release
parameters due to the rapid reactivity and paradoxical effects that high and low local
concentrations of NO elicit.49 As shown in Figure 4B, instantaneous levels of NO generated
from a surface including the maximum instantaneous NO release ([NO]max), should also be
normalized both per unit mass (mol NO mg−1 sec−1) of the scaffold and per unit area of the
substrate (mol NO cm−2 sec−1), as both are influenced by substrate size and coating
thickness.
While the indirect nature of the Griess assay makes accurate quantification of instantaneous
levels of NO difficult compared to chemiluminescence and electrochemistry, mathematical
modeling (i.e., curve fitting and integration) can allow for average NO flux values to be
calculated over extended period.33 Electrochemical detection of NO from a surface may be
complicated due to the spatial dependence of the sensor in relation to the NO-releasing
material. Maintaining consistent electrode-to-material distances are thus crucial for
reproducible and comparable measurements. Although often difficult to measure, the surface
flux of NO at any given time is important for the determination of potential side effects (e.g.,
cytotoxicity to healthy cells) that may be caused by high concentrations of localized NO
release (e.g., at the [NO]max). Furthermore, NO fluxes are paramount to determining the
lifetime of therapeutic utility as NO release thresholds have been determined for many of
NO’s physiological effects. For example, fluxes >21 pmol cm−2 s−1 have been found
necessary to reduce bacterial adhesion. In turn, materials proposed for antimicrobial
applications must be characterized with surface fluxes at or above this level.12 Intermittent
flux values (mol NO cm−2 sec−1 vs. time) and durations that a material is capable of
releasing NO above levels relevant to the proposed application should be determined to
provide the greatest insight into the temporal behavior of the therapeutic material.
3.2 Molecular/particulate NO Release
The use of small molecule and nanomaterial-based NO release vehicles to modulate cellular
activity has generated considerable interest about NO’s therapeutic action from a
pharmacological standpoint. Several research groups have created NO-release scaffolds
capable of delivering NO to specific locations such as tumors and infections. Small
molecules,50, 51 dendrimers,52, 53 proteins,4 gold monolayer protected clusters,5, 54 and silica
nanoparticles6, 55–57 have been investigated as potential NO-donor scaffolds (see Nitric
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Oxide Release Part I: Macromolecular Scaffolds). Whereas surface generated NO is
normalized per area, molecular/particulate NO release quantification should be normalized
per unit mass of the material administered for all necessary characteristics including total
NO released (e.g., mol NO mg−1) and temporal characteristics (e.g., mol NO mg−1 sec−1)
such as the maximum NO release level. Since many applications of NO-releasing
nanotherapeutics are analogous to current medicines, this representation of activity is
essential in order to draw comparisons between drugs with different mechanisms of action.
The NO-release half-life and duration of NO release are once again essential parameters to
be reported because NO donors are capable of releasing NO over wide concentrations and
durations.
3.3 Gaseous NO
Nitric oxide’s delivery from a gas cylinder has limited utility/application relative to NO
delivered from macromolecular scaffolds.58, 59 Nevertheless, inhalation of gaseous NO can
be used to selectively induce vasodilation of pulmonary areas whereas circulating NO
prodrugs produce systemic vasodilation and hypotension effects.60, 61 Treating chronic
wounds with gaseous NO has also been investigated as a strategy to reduce infection and
enhance wound healing.11, 62
With respect to measuring gaseous NO, chemiluminescent detection is clearly the most ideal
method as the NO analysis is conducted in the gas phase.16, 35 The dose is reported as ppm
or ppb. The gaseous concentration administered, the duration of exposure, and the observed
effects (e.g., wound closure time, toxicity) are parameters required to study/compare NO’s
biological action. Of note, the comparison of gaseous NO and macromolecular NO donors
with respect to concentrations and pharmacological efficacy is challenging due to delivery/
exposure means (gas versus solution) and reaction kinetics.59
4. Conclusion
While the potential of NO release as a therapy is becoming more clear, irregular reporting of
NO-release parameters continues to limit the development of NO-based therapeutics
because comparisons between reports is difficult. Thorough analysis and reporting of NO-
release characteristics of proposed therapeutics must remain at the forefront of NO efficacy
studies. Although a number of sensitive methods exist for the quantification of NO, both
their selection and the ensuing data collection/analysis require careful consideration
depending on the NO source and biological matrix. Nitric oxide release characteristics
including [NO]T, td, and instantaneous concentrations (e.g., NO flux) must be normalized by
the amount (e.g., mass or surface area) of material employed to have relevance regarding
NO’s efficacy for a particular condition. As research laboratories inherently utilize distinct
NO analysis methods due to availability, expense, and area of study, NO release must be
represented using standard conventions to allow for comparison of NO payloads and
therapeutic activity between NO scaffolds. Furthermore, the actual NO levels achieved
within a biological system (e.g., cell or tissue) should be addressed and may require tools
not described herein such as molecular probes and/or ultramicroelectrodes.14
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The reaction of nitrite (NO2−) with Griess assay reagents forms an azo dye that is easily
detected spectrophotometrically to extrapolate NO concentrations released from the sample.
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The detection of NO using chemiluminescence involves the reaction of NO with ozone (O3)
to form NO2*. Upon relaxation to NO2, a photon is emitted, which is then detected and is
proportional to the concentration of NO released from the sample.
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Electrochemical detection of NO can be achieved through the oxidation or reduction of NO.
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Graphical representation of (A) total NO release from a surface including designations for
total NO release ([NO]T) and half life of NO release (t1/2) and (B) instantaneous NO release
from a surface with maximum NO flux ([NO]max) and the time to [NO]max (t[NO]max)
indicated.
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Table 1
Concentration dependence of NO’s cellular activity.
Nitric Oxide Concentration Signal Transduction Mechanism Physiological Results References
< 1 – 30 nM Phosphorylation of extracellular signal-regulated
kinases (ERK)
Mediation of proliferative and
protective effects
3, 18,19
30 – 60 nM Phosphorylation of Akt (protein kinases B) Apoptosis protection 3,20–24
100 nM Stabilization of hypoxia-inducible factor 1α (HIF-1α) Tissue injury protection 3,25,26
400 nM Phosphorylation and acetylation of p53 Cytostatic to apoptotic responses,
cell cycle arrest
3,27
> 1 µM Protein nitrosation (poly(ADP-ribose) polymerase,
caspases)
Apoptosis, full cell cycle arrest 3, 28–30
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